CAPLYTA Shows Stronger Remission Results in Phase 3 MDD Data, JNJ Says

Group 1: Company Overview - Johnson & Johnson (NYSE: JNJ) is recognized as one of the 13 Best Dividend Kings to buy in 2026, highlighting its strong dividend performance [1] - The company develops, manufactures, and sells a wide range of healthcare products, supported by ongoing research and development across its various business segments [5] Group 2: Product Development and Pipeline - Johnson & Johnson's main strength lies in its ability to develop new medicines and advanced medical technology, with a diverse pipeline covering areas such as immunology, neuroscience, and metabolic conditions [3] - Recent Phase 3 data analysis showed that CAPLYTA (lumateperone), when used with an antidepressant, resulted in significantly higher remission rates in adults with major depressive disorder compared to placebo, with benefits observed over six months [2] Group 3: Financial Performance - In the third quarter, Johnson & Johnson reported adjusted sales growth of 4.4% year over year, while diluted earnings per share increased by 15.7%, indicating strong financial stability [4] - The demand for Johnson & Johnson's products is not closely tied to the economic cycle, as treatments remain essential for patients even during downturns, contributing to consistent performance [4]